IDH1 and cancer: Mutations in cancer‐associated IDH acquire neoactivity, producing 2‐hydroxyglutarate and leading to decreased activation of hypoxia‐inducible factor 1‐alpha [39], explaining the similarly high CMRO2 in both CET and NEL.